A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs LNA 043 (Primary)
- Indications Cartilage disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 29 Oct 2019 Planned End Date changed from 30 Jan 2020 to 3 Sep 2020.
- 29 Oct 2019 Planned primary completion date changed from 30 Jan 2020 to 3 Sep 2020.
- 09 Sep 2019 Planned End Date changed from 16 Sep 2019 to 30 Jan 2020.